Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 21, 2018, details a series of material definitive agreements entered into by Jaguar Health, Inc. (the "Company") in March 2018. The filings primarily concern a private placement of Series A Convertible Participating Preferred Stock, a concurrent common stock offering, and a secured promissory note. The Company intends to use proceeds from the equity offerings for the commercialization of its product Mytesi and general corporate purposes, while debt proceeds are designated for repaying prior indebtedness.
Key Financial Metrics and Capital Structure
- Preferred Stock Offering: The Company agreed to sell 5,524,926 shares of Series A Convertible Participating Preferred Stock to Sagard Capital Partners, L.P. ("Sagard") for an aggregate purchase price of $9,199,001.
- Common Stock Offering: Concurrently, the Company issued approximately $5.0 million of Common Stock to institutional investors at a price of $0.17 per share.
- Debt Financing: The Company issued a promissory note to Chicago Venture Partners, L.P. ("CVP") with an aggregate principal amount of $1,090,340.91 for a purchase price of $750,000. The note carries an 8% annual interest rate and matures on September 21, 2019.
- Debt Repayment: Proceeds from the CVP Note Offering were used to fully repay the Hercules Loan and other prior secured and unsecured indebtedness.
- Management Fees: A three-year management services agreement was signed with an affiliate of Sagard for an annual fee of $450,000, payable in installments beginning in the second year.
Material Changes and Terms
The filing outlines significant changes to the Company's capital structure and governance:
- Conversion Terms: Preferred Shares are convertible into Common Stock at an effective price of $0.185 per share (9:1 ratio). Conversion is subject to a 19.99% beneficial ownership limitation until stockholder approval is obtained.
- Redemption Rights:
- Optional Redemption: The Company may redeem shares after one year at 2x the original issue price ($3.33 per share) if certain conditions are met.
- Mandatory Redemption: Holders may require redemption at $2.3057 per share if Mytesi revenues for the six months ended March 31, 2021, are less than $22 million, or if the stock price averages below $1.00, or if the Company fails to file its 10-Q by June 30, 2021.
- Board Composition: The Board of Directors was expanded from seven to nine members. Jeffrey C. Johnson, a partner at Sagard Holdings, was appointed as a Class III director and member of the Compensation Committee.
- Covenants: The Preferred Stock agreement includes covenants restricting the Company from issuing senior stock, incurring new debt, or making acquisitions without investor consent while the Preferred Stock is outstanding.
Outlook, Risks, and Contingencies
Management commentary indicates a focus on commercializing Mytesi. However, the financing structure introduces specific risks and contingencies:
- Performance Triggers: The mandatory redemption provision creates a financial contingency tied to revenue targets ($22 million in six months) and stock price performance ($1.00 average) by 2021.
- Liquidity and Registration: The Company is obligated to file a registration statement on Form S-3 to register the conversion shares. Failure to do so results in liquidated damages of 0.5% per 30-day period.
- Security Interest: CVP holds a security interest in substantially all of the Company's assets following the repayment of the Hercules Loan.
- Lock-up Period: Sagard's Preferred Shares are subject to a 12-month lock-up period.
Investor Verification Checklist
- Verify the exact closing date and receipt of funds for the $9.2 million Preferred Stock and $5.0 million Common Stock offerings.
- Confirm the status of the Form S-3 registration statement filing required for the resale of conversion shares.
- Monitor Mytesi revenue performance against the $22 million six-month threshold to assess mandatory redemption risk.
- Review the Company's cash flow projections to ensure ability to meet the $450,000 annual management fee starting in year two.
- Check for any subsequent filings regarding the 19.99% beneficial ownership limitation and stockholder approval status.